Pipeline

i n f l a r x

Loading

Development Pipeline

Home R & D Pipeline

Pipeline

COVID 19 & ARDS

Program

Preclinical

Phase 1

Phase 2

Phase 3

Market

Status & Milestones

Vilobelimab
C5a inhibitor

Critical COVID-19

SARS-CoV-2-induced ARDS

Approved by European Commission*

Broader ARDS

Phase 2 "Just Breathe" ASPR/BARDA clinical platform study

INFLAMMATION & IMMUNOLOGY (I&I)

Program

Preclinical

Phase 1

Phase 2

Phase 3

Market

Status & Milestones

Vilobelimab
C5a inhibitor

Pyoderma Gangraenosum

Enrollment ongoing;
Interim analysis for adaption and futility anticipated in 2Q 2025

INF904
oral C5aR inhibitor

Chronic spontaneous urticaria (CSU)

Data anticipated in summer 2025

Hidradenitis suppurativa (HS)

Data anticipated in summer 2025

I&I indications

Additional indications in I&I, including neurology, nephrology, hematology and others

IFX002
C5a inhibitor

Chronic inflammatory conditions

For optimized use in chronic inflammation

*Commercial partnering and distribution options in the EU being considered.

See also in R&D: